Podoplanin, α-Smooth Muscle Actin or S100A4 Expressing Cancer-Associated Fibroblasts Are Associated with Different Prognosis in Colorectal Cancers

The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we an...

Full description

Saved in:
Bibliographic Details
Published inJournal of Korean medical science Vol. 28; no. 9; pp. 1293 - 1301
Main Authors Choi, Song-Yi, Sung, Rohyun, Lee, Sang-Jeon, Lee, Taek-Gu, Kim, Nayoung, Yoon, Soon Man, Lee, Eun Jeoung, Chae, Hee Bok, Youn, Sei Jin, Park, Seon Mee
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Academy of Medical Sciences 01.09.2013
대한의학회
Subjects
Online AccessGet full text
ISSN1011-8934
1598-6357
1598-6357
DOI10.3346/jkms.2013.28.9.1293

Cover

Abstract The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC.
AbstractList The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC.The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC.
The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC.
The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA),and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front,PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN+ CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN−/α-SMAhigh CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN−/S100A4high CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN+ CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN−/α-SMAhigh or PDPN−/S100A4high CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC. KCI Citation Count: 1
The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN + CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN - /α-SMA high CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN - /S100A4 high CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN + CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN - /α-SMA high or PDPN - /S100A4 high CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC.
Author Choi, Song-Yi
Chae, Hee Bok
Kim, Nayoung
Lee, Taek-Gu
Lee, Eun Jeoung
Youn, Sei Jin
Lee, Sang-Jeon
Sung, Rohyun
Yoon, Soon Man
Park, Seon Mee
AuthorAffiliation 2 Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea
1 Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea
4 Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
AuthorAffiliation_xml – name: 4 Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
– name: 1 Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea
– name: 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
– name: 2 Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea
Author_xml – sequence: 1
  givenname: Song-Yi
  surname: Choi
  fullname: Choi, Song-Yi
  organization: Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 2
  givenname: Rohyun
  surname: Sung
  fullname: Sung, Rohyun
  organization: Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 3
  givenname: Sang-Jeon
  surname: Lee
  fullname: Lee, Sang-Jeon
  organization: Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 4
  givenname: Taek-Gu
  surname: Lee
  fullname: Lee, Taek-Gu
  organization: Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 5
  givenname: Nayoung
  orcidid: 0000-0002-9397-0406
  surname: Kim
  fullname: Kim, Nayoung
  organization: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
– sequence: 6
  givenname: Soon Man
  surname: Yoon
  fullname: Yoon, Soon Man
  organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 7
  givenname: Eun Jeoung
  surname: Lee
  fullname: Lee, Eun Jeoung
  organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 8
  givenname: Hee Bok
  orcidid: 0000-0002-9711-6434
  surname: Chae
  fullname: Chae, Hee Bok
  organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 9
  givenname: Sei Jin
  surname: Youn
  fullname: Youn, Sei Jin
  organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
– sequence: 10
  givenname: Seon Mee
  surname: Park
  fullname: Park, Seon Mee
  organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24015033$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001802018$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9UktuFDEQtVAQ-cAJkJCXLOjGdvXPG6TWkECkICIS1pbH7Z440213bA8k5-AkXIQz4c6E4bNg5ZLrfcqud4j2rLMaoeeU5ABF9fp6PYacEQo5a3KeU8bhETqgJW-yCsp6L9WE0qzhUOyjwxCuCWFlyeAJ2mcFoSUBOEDfzl3npkFaY1_hH9-zi9G5eIU_bIIaNG5VNBY7jy8oIW2Bj28nr0MwdoUX0irtszYEp4yMusMnZundcpAhBtz6RP7d-mqS5lvT99prG_G5dyvrggk4qS_c4LxWUQ4PmuEpetzLIehnD-cR-nxyfLl4n519fHe6aM8yVUATM7osZcNYB6qrK6arkirS90A4mSuquGx6SZgEArwqCANa1MC7oiuV6tMVHKGXW13re7FWRjhp7s-VE2sv2k-Xp6KsIfES9M0WOm2Wo-5UeoWXg5i8GaW_uyf-3bHmKsl8EVBXQJP3zmvy7majQxSjCUoP6ee12wSRPNICE3Ye68WfXjuTX0tLANgClHcheN3vIJSIORpijoaYoyFYI7iYo5FY_B-WMlFG4-aBzfBf7k_6osFq
CitedBy_id crossref_primary_10_1016_j_canlet_2021_07_006
crossref_primary_10_18632_oncotarget_20074
crossref_primary_10_18632_oncotarget_20076
crossref_primary_10_3390_cancers13081759
crossref_primary_10_17116_patol20218304122
crossref_primary_10_1097_MD_0000000000015164
crossref_primary_10_1016_j_cca_2016_08_008
crossref_primary_10_1016_j_bj_2020_09_006
crossref_primary_10_1016_j_dld_2022_12_007
crossref_primary_10_3390_cancers14184394
crossref_primary_10_1002_cam4_1704
crossref_primary_10_1038_s41388_024_02953_1
crossref_primary_10_1186_s12964_023_01125_0
crossref_primary_10_1186_s12929_024_01099_2
crossref_primary_10_7759_cureus_53949
crossref_primary_10_3390_cancers13020183
crossref_primary_10_1158_0008_5472_CAN_21_0614
crossref_primary_10_3389_fcell_2021_733270
crossref_primary_10_3892_ol_2017_7335
crossref_primary_10_1038_s41467_021_27599_5
crossref_primary_10_2217_fon_2017_0054
crossref_primary_10_1007_s13277_016_5293_6
crossref_primary_10_1159_000531695
crossref_primary_10_18632_oncotarget_7445
crossref_primary_10_3390_cancers12102949
crossref_primary_10_1002_path_5224
crossref_primary_10_3390_cancers13143466
crossref_primary_10_1089_omi_2020_0023
crossref_primary_10_1093_ajcp_aqae145
crossref_primary_10_3892_ol_2018_8097
crossref_primary_10_1038_s41416_020_0973_9
crossref_primary_10_18632_oncotarget_19869
crossref_primary_10_1002_cac2_12291
crossref_primary_10_1007_s13193_022_01653_0
crossref_primary_10_1097_PAS_0000000000002075
crossref_primary_10_1136_jcp_2024_209604
crossref_primary_10_1038_s41392_019_0100_7
crossref_primary_10_32604_biocell_2023_030541
crossref_primary_10_1155_2019_6240505
crossref_primary_10_1111_pcmr_12657
crossref_primary_10_3390_ijms21207714
crossref_primary_10_17116_patol20208201168
crossref_primary_10_3390_ijms21218119
crossref_primary_10_1007_s12094_021_02734_2
crossref_primary_10_1371_journal_pone_0152523
crossref_primary_10_3390_biology11071014
crossref_primary_10_17116_patol20228405111
crossref_primary_10_1016_j_isci_2024_110701
crossref_primary_10_1111_cpr_13592
Cites_doi 10.1158/1078-0432.CCR-06-1746
10.1053/j.gastro.2009.12.010
10.1016/j.yexcr.2010.02.045
10.1002/ijc.25358
10.1093/jjco/28.10.615
10.1016/j.gde.2009.01.003
10.1159/000226112
10.1038/modpathol.3800580
10.1002/ijc.23611
10.1007/s10549-012-1984-x
10.1111/j.1442-2050.2011.01211.x
10.4161/cbt.5.12.3354
10.1093/jnci/djh034
10.1002/ijc.2910400116
10.1007/s00418-012-0998-0
10.1158/1078-0432.CCR-06-2191
10.1007/BF00690602
10.1177/1066896912471851
10.1016/j.biocel.2006.11.005
10.5858/2009-0114-OA.1
10.1038/sj.bjc.6603651
10.2353/ajpath.2010.090526
10.1097/PAS.0b013e318184cd55
10.1158/1535-7163.MCT-11-0340
ContentType Journal Article
Copyright 2013 The Korean Academy of Medical Sciences. 2013
Copyright_xml – notice: 2013 The Korean Academy of Medical Sciences. 2013
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3346/jkms.2013.28.9.1293
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1598-6357
EndPage 1301
ExternalDocumentID oai_kci_go_kr_ARTI_573314
PMC3763102
24015033
10_3346_jkms_2013_28_9_1293
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
29K
2WC
3O-
5-W
53G
5GY
8JR
8XY
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EF.
EJD
F5P
FRP
GROUPED_DOAJ
GX1
HYE
KQ8
M48
O5R
O5S
OK1
OVT
PGMZT
RNS
RPM
TR2
W2D
XSB
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c438t-1b5a822d3cd762e651c0ff309051c01c9a8fa02a30396402314739d4d5ccf3963
IEDL.DBID M48
ISSN 1011-8934
1598-6357
IngestDate Sun Mar 09 07:55:17 EDT 2025
Thu Aug 21 13:51:52 EDT 2025
Fri Jul 11 11:49:16 EDT 2025
Thu Apr 03 07:00:24 EDT 2025
Tue Jul 01 01:44:48 EDT 2025
Thu Apr 24 23:01:39 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Colorectal Neoplasms
Cancer-Associated Fibroblast
S100A4
α-Smooth Muscle Actin
Podoplanin
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c438t-1b5a822d3cd762e651c0ff309051c01c9a8fa02a30396402314739d4d5ccf3963
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000345.2013.28.9.015
ORCID 0000-0002-9711-6434
0000-0002-9397-0406
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2013.28.9.1293
PMID 24015033
PQID 1431296316
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_573314
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3763102
proquest_miscellaneous_1431296316
pubmed_primary_24015033
crossref_primary_10_3346_jkms_2013_28_9_1293
crossref_citationtrail_10_3346_jkms_2013_28_9_1293
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-09-01
PublicationDateYYYYMMDD 2013-09-01
PublicationDate_xml – month: 09
  year: 2013
  text: 2013-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of Korean medical science
PublicationTitleAlternate J Korean Med Sci
PublicationYear 2013
Publisher The Korean Academy of Medical Sciences
대한의학회
Publisher_xml – name: The Korean Academy of Medical Sciences
– name: 대한의학회
References Ngan (10.3346/jkms.2013.28.9.1293_ref3) 2007; 96
Mesker (10.3346/jkms.2013.28.9.1293_ref20) 2007; 29
McAnulty (10.3346/jkms.2013.28.9.1293_ref18) 2007; 39
Tsujino (10.3346/jkms.2013.28.9.1293_ref2) 2007; 13
Boye (10.3346/jkms.2013.28.9.1293_ref27) 2010; 176
Grégoire (10.3346/jkms.2013.28.9.1293_ref5) 1995; 14
Martin (10.3346/jkms.2013.28.9.1293_ref6) 1987; 40
Tong (10.3346/jkms.2013.28.9.1293_ref22) 2012; 25
Schulte (10.3346/jkms.2013.28.9.1293_ref11) 2012; 138
Wang (10.3346/jkms.2013.28.9.1293_ref16) 2009; 33
Umar (10.3346/jkms.2013.28.9.1293_ref14) 2004; 96
Schoppmann (10.3346/jkms.2013.28.9.1293_ref24) 2012; 134
Ostman (10.3346/jkms.2013.28.9.1293_ref28) 2009; 19
Liotta (10.3346/jkms.2013.28.9.1293_ref7) 1983; 49
Kawase (10.3346/jkms.2013.28.9.1293_ref21) 2008; 123
Brennen (10.3346/jkms.2013.28.9.1293_ref30) 2012; 11
Yamanashi (10.3346/jkms.2013.28.9.1293_ref10) 2009; 77
Dumoff (10.3346/jkms.2013.28.9.1293_ref25) 2006; 19
Kono (10.3346/jkms.2013.28.9.1293_ref8) 2007; 31
Boland (10.3346/jkms.2013.28.9.1293_ref13) 1998; 58
American Joint Committee on Cancer (10.3346/jkms.2013.28.9.1293_ref15) 2009
Henry (10.3346/jkms.2013.28.9.1293_ref17) 2007; 13
Cheng (10.3346/jkms.2013.28.9.1293_ref4) 2002; 62
Sugimoto (10.3346/jkms.2013.28.9.1293_ref26) 2006; 5
Kitano (10.3346/jkms.2013.28.9.1293_ref9) 2010; 134
Vered (10.3346/jkms.2013.28.9.1293_ref12) 2010; 127
Pino (10.3346/jkms.2013.28.9.1293_ref29) 2010; 138
Nakayama (10.3346/jkms.2013.28.9.1293_ref19) 1998; 28
Foschini (10.3346/jkms.2013.28.9.1293_ref23) 2013; 21
Pietras (10.3346/jkms.2013.28.9.1293_ref1) 2010; 316
12183436 - Cancer Res. 2002 Aug 15;62(16):4767-72
6317982 - Lab Invest. 1983 Dec;49(6):636-49
14970275 - J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
16528371 - Mod Pathol. 2006 May;19(5):708-16
20211171 - Exp Cell Res. 2010 May 1;316(8):1324-31
17196874 - Int J Biochem Cell Biol. 2007;39(4):666-71
20340130 - Int J Cancer. 2010 Sep 1;127(6):1356-62
20923309 - Arch Pathol Lab Med. 2010 Oct;134(10):1520-7
20026115 - Gastroenterology. 2010 Apr;138(4):1406-17
17404090 - Clin Cancer Res. 2007 Apr 1;13(7):2082-90
9823339 - Cancer Res. 1998 Nov 15;58(22):5248-57
22820858 - Histochem Cell Biol. 2012 Dec;138(6):847-60
3298078 - Int J Cancer. 1987 Jul 15;40(1):87-93
23349470 - Int J Surg Pathol. 2013 Apr;21(2):133-41
22323494 - Mol Cancer Ther. 2012 Feb;11(2):257-66
18546264 - Int J Cancer. 2008 Sep 1;123(5):1053-9
9839502 - Jpn J Clin Oncol. 1998 Oct;28(10):615-20
17726261 - Cell Oncol. 2007;29(5):387-98
22350732 - Breast Cancer Res Treat. 2012 Jul;134(1):237-44
21895849 - Dis Esophagus. 2012 Jan;25(1):72-80
17325702 - Br J Cancer. 2007 Mar 26;96(6):986-92
19211240 - Curr Opin Genet Dev. 2009 Feb;19(1):67-73
19556810 - Oncology. 2009;77(1):53-62
18971777 - Am J Surg Pathol. 2009 Jan;33(1):134-41
17671675 - Int J Oncol. 2007 Sep;31(3):501-8
8821094 - Cancer Metastasis Rev. 1995 Dec;14(4):339-50
20019188 - Am J Pathol. 2010 Feb;176(2):528-35
17363526 - Clin Cancer Res. 2007 Mar 15;13(6):1736-41
17106243 - Cancer Biol Ther. 2006 Dec;5(12):1640-6
References_xml – volume: 58
  start-page: 5248
  year: 1998
  ident: 10.3346/jkms.2013.28.9.1293_ref13
  publication-title: Cancer Res
– volume: 13
  start-page: 1736
  year: 2007
  ident: 10.3346/jkms.2013.28.9.1293_ref17
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1746
– volume: 138
  start-page: 1406
  year: 2010
  ident: 10.3346/jkms.2013.28.9.1293_ref29
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.12.010
– volume: 316
  start-page: 1324
  year: 2010
  ident: 10.3346/jkms.2013.28.9.1293_ref1
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2010.02.045
– volume: 127
  start-page: 1356
  year: 2010
  ident: 10.3346/jkms.2013.28.9.1293_ref12
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25358
– volume: 28
  start-page: 615
  year: 1998
  ident: 10.3346/jkms.2013.28.9.1293_ref19
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/28.10.615
– volume: 19
  start-page: 67
  year: 2009
  ident: 10.3346/jkms.2013.28.9.1293_ref28
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/j.gde.2009.01.003
– volume: 31
  start-page: 501
  year: 2007
  ident: 10.3346/jkms.2013.28.9.1293_ref8
  publication-title: Int J Oncol
– volume: 77
  start-page: 53
  year: 2009
  ident: 10.3346/jkms.2013.28.9.1293_ref10
  publication-title: Oncology
  doi: 10.1159/000226112
– volume: 19
  start-page: 708
  year: 2006
  ident: 10.3346/jkms.2013.28.9.1293_ref25
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.3800580
– volume: 29
  start-page: 387
  year: 2007
  ident: 10.3346/jkms.2013.28.9.1293_ref20
  publication-title: Cell Oncol
– volume: 123
  start-page: 1053
  year: 2008
  ident: 10.3346/jkms.2013.28.9.1293_ref21
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23611
– volume: 62
  start-page: 4767
  year: 2002
  ident: 10.3346/jkms.2013.28.9.1293_ref4
  publication-title: Cancer Res
– volume: 134
  start-page: 237
  year: 2012
  ident: 10.3346/jkms.2013.28.9.1293_ref24
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-012-1984-x
– volume: 25
  start-page: 72
  year: 2012
  ident: 10.3346/jkms.2013.28.9.1293_ref22
  publication-title: Dis Esophagus
  doi: 10.1111/j.1442-2050.2011.01211.x
– volume: 5
  start-page: 1640
  year: 2006
  ident: 10.3346/jkms.2013.28.9.1293_ref26
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.5.12.3354
– volume: 96
  start-page: 261
  year: 2004
  ident: 10.3346/jkms.2013.28.9.1293_ref14
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djh034
– volume: 40
  start-page: 87
  year: 1987
  ident: 10.3346/jkms.2013.28.9.1293_ref6
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910400116
– volume: 138
  start-page: 847
  year: 2012
  ident: 10.3346/jkms.2013.28.9.1293_ref11
  publication-title: Histochem Cell Biol
  doi: 10.1007/s00418-012-0998-0
– volume: 13
  start-page: 2082
  year: 2007
  ident: 10.3346/jkms.2013.28.9.1293_ref2
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2191
– volume: 49
  start-page: 636
  year: 1983
  ident: 10.3346/jkms.2013.28.9.1293_ref7
  publication-title: Lab Invest
– volume: 14
  start-page: 339
  year: 1995
  ident: 10.3346/jkms.2013.28.9.1293_ref5
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/BF00690602
– volume: 21
  start-page: 133
  year: 2013
  ident: 10.3346/jkms.2013.28.9.1293_ref23
  publication-title: Int J Surg Pathol
  doi: 10.1177/1066896912471851
– volume: 39
  start-page: 666
  year: 2007
  ident: 10.3346/jkms.2013.28.9.1293_ref18
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2006.11.005
– volume: 134
  start-page: 1520
  year: 2010
  ident: 10.3346/jkms.2013.28.9.1293_ref9
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/2009-0114-OA.1
– volume: 96
  start-page: 986
  year: 2007
  ident: 10.3346/jkms.2013.28.9.1293_ref3
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603651
– volume: 176
  start-page: 528
  year: 2010
  ident: 10.3346/jkms.2013.28.9.1293_ref27
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2010.090526
– volume-title: Manual for staging of cancer
  year: 2009
  ident: 10.3346/jkms.2013.28.9.1293_ref15
– volume: 33
  start-page: 134
  year: 2009
  ident: 10.3346/jkms.2013.28.9.1293_ref16
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e318184cd55
– volume: 11
  start-page: 257
  year: 2012
  ident: 10.3346/jkms.2013.28.9.1293_ref30
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-11-0340
– reference: 20340130 - Int J Cancer. 2010 Sep 1;127(6):1356-62
– reference: 17196874 - Int J Biochem Cell Biol. 2007;39(4):666-71
– reference: 16528371 - Mod Pathol. 2006 May;19(5):708-16
– reference: 9823339 - Cancer Res. 1998 Nov 15;58(22):5248-57
– reference: 18546264 - Int J Cancer. 2008 Sep 1;123(5):1053-9
– reference: 18971777 - Am J Surg Pathol. 2009 Jan;33(1):134-41
– reference: 19556810 - Oncology. 2009;77(1):53-62
– reference: 20019188 - Am J Pathol. 2010 Feb;176(2):528-35
– reference: 22820858 - Histochem Cell Biol. 2012 Dec;138(6):847-60
– reference: 8821094 - Cancer Metastasis Rev. 1995 Dec;14(4):339-50
– reference: 17106243 - Cancer Biol Ther. 2006 Dec;5(12):1640-6
– reference: 3298078 - Int J Cancer. 1987 Jul 15;40(1):87-93
– reference: 9839502 - Jpn J Clin Oncol. 1998 Oct;28(10):615-20
– reference: 22323494 - Mol Cancer Ther. 2012 Feb;11(2):257-66
– reference: 20211171 - Exp Cell Res. 2010 May 1;316(8):1324-31
– reference: 19211240 - Curr Opin Genet Dev. 2009 Feb;19(1):67-73
– reference: 22350732 - Breast Cancer Res Treat. 2012 Jul;134(1):237-44
– reference: 12183436 - Cancer Res. 2002 Aug 15;62(16):4767-72
– reference: 21895849 - Dis Esophagus. 2012 Jan;25(1):72-80
– reference: 17671675 - Int J Oncol. 2007 Sep;31(3):501-8
– reference: 23349470 - Int J Surg Pathol. 2013 Apr;21(2):133-41
– reference: 17404090 - Clin Cancer Res. 2007 Apr 1;13(7):2082-90
– reference: 6317982 - Lab Invest. 1983 Dec;49(6):636-49
– reference: 14970275 - J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
– reference: 20026115 - Gastroenterology. 2010 Apr;138(4):1406-17
– reference: 17325702 - Br J Cancer. 2007 Mar 26;96(6):986-92
– reference: 20923309 - Arch Pathol Lab Med. 2010 Oct;134(10):1520-7
– reference: 17363526 - Clin Cancer Res. 2007 Mar 15;13(6):1736-41
– reference: 17726261 - Cell Oncol. 2007;29(5):387-98
SSID ssj0025523
Score 2.2363815
Snippet The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF)...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1293
SubjectTerms Actins - immunology
Actins - metabolism
Adult
Aged
Aged, 80 and over
Antibodies - immunology
Biomarkers, Tumor - metabolism
Carcinoembryonic Antigen - blood
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Disease-Free Survival
Female
Fibroblasts - cytology
Fibroblasts - metabolism
Humans
Immunohistochemistry
Lymphatic Metastasis
Male
Membrane Glycoproteins - immunology
Membrane Glycoproteins - metabolism
Middle Aged
Neoplasm Staging
Original
Phenotype
Prognosis
S100 Calcium-Binding Protein A4
S100 Proteins - immunology
S100 Proteins - metabolism
의학일반
Title Podoplanin, α-Smooth Muscle Actin or S100A4 Expressing Cancer-Associated Fibroblasts Are Associated with Different Prognosis in Colorectal Cancers
URI https://www.ncbi.nlm.nih.gov/pubmed/24015033
https://www.proquest.com/docview/1431296316
https://pubmed.ncbi.nlm.nih.gov/PMC3763102
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001802018
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Korean Medical Science, 2013, 28(9), 180, pp.1293-1301
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLa2ISFuJv4pjMpIXM5VHLtpfIFQ1a3aQEWTRqXdWbHjjKqdsyWpNJ6DJ-FFeCbOyU-haHDBVaXGP1HOsc_32UffIeQtN8bJyEUsA7zLZKwSBrQ5ZU6ZzISAUHl94Db7FJ3M5YeL4cUO6aqith-wvJPaYT2pebEa3N58fQ8L_h0yToE3lMsrFN7mYhDGAzXACLZL7kFoipCNzeTmWgHgc9hk3HPOIFDLRobob4OgULDEEwEhtqLWri-yuwDpn3mVvwWq6UOy3yJMOm5c4hHZcf4xuT9r79CfkG9nwESvV4lf-EP64zs7v8rBWnS2LqE5HcP-52le0HMeBGNJj2-bTFl_SSfoIAXrDOpSOgWunRvA31UJ80HnX4_wfJcetdVXKnpW5JjRtygpjD6BDRc3WnjLZszyKZlPjz9PTlhbmoFZKeKKcTNMAFqkwqawm7poyG2QZSJAtS8bcKuSOEuCMIEAqSKJGnNyJFQq06G1GfwlnpE9n3v3gtAkdCoLRspIMIh1UmUOYGAahdZZY4XqkbD79Nq2uuVYPmOlgb-g6TSaTqPpdBhrpdF0PXK46XTdyHb8u_kbsKle2oVGuW38vcz1stBAKk41SkZyCW06i2tYgnivkniXr0tgTwIGiQSPeuR54wGbSTsH6pHRlm9sGuB820_84kst841bP8C_l__d8xV5ENbFOzAj7oDsVcXavQYIVZk-kIfTj_36AKJfL5Gf2vIcCA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Podoplanin%2C+%CE%B1-Smooth+Muscle+Actin+or+S100A4+Expressing+Cancer-Associated+Fibroblasts+Are+Associated+with+Different+Prognosis+in+Colorectal+Cancers&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Choi%2C+Song-Yi&rft.au=Sung%2C+Rohyun&rft.au=Lee%2C+Sang-Jeon&rft.au=Lee%2C+Taek-Gu&rft.date=2013-09-01&rft.pub=The+Korean+Academy+of+Medical+Sciences&rft.issn=1011-8934&rft.eissn=1598-6357&rft.volume=28&rft.issue=9&rft.spage=1293&rft.epage=1301&rft_id=info:doi/10.3346%2Fjkms.2013.28.9.1293&rft_id=info%3Apmid%2F24015033&rft.externalDocID=PMC3763102
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon